| Trial ID: | L4022 |
| Source ID: | NCT00572650
|
| Associated Drug: |
Vildagliptin
|
| Title: |
Pharmacokinetic Study of LAF237 and Its Metabolites in Mild Renal Impaired Patients
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: vildagliptin
|
| Outcome Measures: |
Primary: Pharmacokinetic measures, throughout the study | Secondary: Safety and tolerability measures, throughout the study
|
| Sponsor/Collaborators: |
Sponsor: Novartis
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
29
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2007-10
|
| Completion Date: |
2007-11
|
| Results First Posted: |
|
| Last Update Posted: |
2012-05-02
|
| Locations: |
Novartis Investigator Site, Kiel, Germany
|
| URL: |
https://clinicaltrials.gov/show/NCT00572650
|
